Illumina, Inc. (NASDAQ: ILMN) and MyOme, a leading genomics innovation and risk modeling company, today announced a collaboration and investment by Illumina into MyOme. The collaboration and investmen ...

Recent industry reports have highlighted past and projected rapid expansion in the DNA diagnostics and genomics markets, driven by liquid biopsies, direct-to-consumer testing, and personalized ...

Illumina (ILMN) and MyOme announced a collaboration and investment by Illumina into MyOme. The collaboration and investment will help advance ...

With the MiSeq™ i100 Series, Illumina continues to set the highest standards.Advancements in system design, sequencing chemistry, and data analysis deliverthe simplest, fastest benchtop sequencing and ...

Illumina (ILMN) has been grinding higher over the past month, even though the stock is still down over the past year, raising a simple question for investors: is this quiet rebound worth leaning into?

Former deputy prime minister, who left Meta this year, to be joined by Facebook-owner’s chief AI scientist ...

The next generation sequencing market offers significant opportunities by enhancing the diagnosis and treatment of chronic ...

Cell free RNA diagnostics market is projected to reach US$ 204.5 Mn by 2035, expanding at a CAGR of 14.5% from 2025 to 2035 ...

Get a Free Sample PDF copy of the report @- The trajectory of the Epigenetics Market is shaped by a myriad of factors. Firstly, the growing application of epigenetics in non-oncology diseases and the ...

Experienced senior executive brings proven track record in financial strategy, operational excellence, and commercial execution ...

Selected U.S. Privacy & Cyber Updates - SEC Dismisses Remaining Claims Against SolarWinds - On November 20, 2025, the Securities and ...

In a wide-ranging discussion on the future of genomics and cancer diagnostics in India, senior leaders from Strand Life ...